ADDvise Group AB receives SEK 27.8 million through the warrants of series 2019/2021 – Regulatory information

10-02-2021   Regulatory press release

Holders of warrants of series 2019/2021 subscribed for 42,787,137 warrants, corresponding to 99.41 percent of the outstanding warrants, for subscription of 42,787,137 shares of series B at the subscribtion price of SEK 0.65. Through the exercise of the warrants, ADDvise receives SEK 27,811,639 before issue costs.

Background

During the first quarter of 2019, ADDvise carried out a rights issue of units, consisting of one (1) newly issued series B share and one (1) warrant of series 2019/2021. Each warrant of series 2019/2021 entitled the holder to subscribe for one (1) new B share in ADDvise. The subcription period ran January 25, 2021 and February 8, 2021.

Exercised warrants have been replaced with interim shares (IA) pending registration at Bolagsverket. The conversion of interim shares into shares of series B is expected to take place within approximately three weeks.

Complete terms and conditions for the warrants are available on the Company's website, www.addvisegroup.se.

Number of shares and share capital

Through the exercise of the warrants, the number of shares in ADDvise increases by 42,787,137 shares, from 96,913,631 to 139,700,768 shares. The share capital increases by SEK 4,278,713,7 from SEK 9,691,363.1 to SEK 13,970,076,8.

For existing shareholders who have not exercised any warrants of series 2019/2021, the dilution amounts to approximately 31.08 percent.

Adviser

Mangold Fondkommission is financial adviser and Advokatfirman Schjødt is legal advisor to ADDvise in connection with the exercise of warrants of series 2019/2021.

For questions regarding the warrants, please contact:

Mangold Fondkommission AB

Tel: +46 8 5030 1595

E-mail: emissioner@mangold.se

For further information:

Hanna Myhrman, General Counsel
Tel: +46 709 82 92 23
E-mail:
hanna.myhrman@addvisegroup.se

Important information:

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on 10 February 2021 at 08:00 CET.

About ADDvise

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business - both geographically and product wise. ADDvise Group's shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, +46 8 503 015 50, ca@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

Latest press releases

ADDvise announces preliminary result for 2022 which is stronger than expected

Regulatory

The preliminary result for ADDvise Group for the full year 2022 significantly deviates from what ADDvise Group considers to be current market expectations. [image] The net sales pro forma full year 2022 rolling 12 months amounted to SEK 1,097 million with an adjusted EBITDA pro forma of SEK 241 million. The financial targets for the…

ADDvise receives order worth USD 3.5 million

Regulatory

ADDvise Group AB’s subsidiary Poly Pharmaceuticals Inc has received an order from AxisCare Health Logistics Inc, a company distributing equipment and medical supplies to hospitals, clinics, medical offices and medical equipment suppliers. The order is worth approximately USD 3.5 million. The order consists of delivery of the prescription dietary supplemental Folite, developed and manufactured by…

ADDvise receives order worth USD 1.8 million

Regulatory

ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from Nasser Saeed Al Hajri & Partners Contracting (NHS & Partners), a leading construction contractor in the United Arab Emirates. The order is worth approximately USD 1.8 million. The order involves the detailed design, supply and installation of an ISO 8 and ISO 7…